3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
2
NIH
1
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
4
Polycythemia Vera
3
Myeloproliferative Disorders
3
Stomach Neoplasms
2
Cardiovascular Diseases
2
Multiple Myeloma
1
Hemorrhage
1
Gastrointestinal Neoplasms
1
Esophageal Neoplasms
1
Barrett Esophagus
1
Adenomatous Polyps
1
Adenoma
1
Interventions
pembrolizumab
40
Cisplatin
25
Fluorouracil
24
Paclitaxel
21
Oxaliplatin
16
Capecitabine
12
Leucovorin
10
Irinotecan
10
Docetaxel
10
Gemcitabine
8
Carboplatin
7
atezolizumab
6
Nivolumab
6
Bevacizumab
6
Trastuzumab
5
Ramucirumab
5
Radiotherapy
5
spartalizumab
4
Albumin-Bound Paclitaxel
4
zanidatamab
3
tisotumab vedotin
3
patritumab deruxtecan
3
lenvatinib
3
fludarabine
3
durvalumab
3
Radiation
3
Drug Therapy
3
Cyclophosphamide
3
130-nm albumin-bound paclitaxel
3
zimberelimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Esophageal Neoplasms
×
Aspirin
×
Clear all
NCT04081831
2022-04-19
ENgAGE-HK
Bayer
Completed
99,999 enrolled